Fig. 2

AZD9496, like fulvestrant, inhibits tumour growth and ER signalling in vivo in the presence of E2. Mice bearing MCF7 xenografts in the presence of exogenous E2 were randomised to continued E2 or switched to ED, all plus vehicle (Veh), fulvestrant (Ful), or AZD9496 (9496), and monitored for 8 days. a Tumour growth curve of MCF7 cells in E2 or ED condition in the presence of vehicle, fulvestrant, or AZD9496 (n = 4–5). Graphs show the model-predicted values and 95% confidence intervals at each time point. For display purposes, predicted values have been ‘normalised’ by dividing predicted values and 95% confidence limits by the day 0 treatment group predicted value. Measurements of individual tumour sizes from each mouse were normalised in the same manner and plotted. b Representative ER IHC and quantification of ER protein level by IHC using H-score. c Immunoblot of ER downstream target gene PR and β-actin control in available E2 or ED-treated tumours. d Log2 fold change of the average gene expression in tumours from each treatment group. Heat map of genes differentially expressed in the E2 treated groups. SEM are shown; *p < 0.05; **p < 0.01; ***p < 0.001